1. Scrip
  2. >>Focus On Asia
  3. >>Japan

MSD To Launch Rotavirus Vaccine Rotateq In Japan

Merck & Co. subsidiary Merck Sharp & Dohme Ltd. announced on July 13 that it will launch Rotateq as an oral vaccine against rotavirus gastroenteritis, a condition seen in children, on July 20.

Merck & Co. subsidiaryMerck Sharp & Dohme Ltd.announced on July 13 that it will launch Rotateq as an oral vaccine against rotavirus gastroenteritis, a condition seen in children, on July 20. Most children who suffer from the rotavirus are infected by the illness by the age of 5, experiencing diarrhea, vomiting, and fever, but complications can also lead to dehydration, cramps, and even encephalitis. Currently, only symptomatic treatment exists for the illness, but MSD aims to spread prevention through vaccination. Rotavirus has many serotypes, but 90% of cases are caused by G1P(8), G2P(4), G3P(8), G4P(8), or (G9P(8). The vaccine targets these serotypes with a 100% efficacy against severe rotavirus gastroenteritis. (Click Here For More – Japanese Language)

“MSD: Rotavirus Vaccine Rotateq On Sale From July 20” mixonline.jp 7/12/2012

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

More from Focus On Asia

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.